There are two routes to tirzepatide, differing in price, regulation, and oversight.
Brand (Zepbound, Mounjaro)
FDA-approved tirzepatide from Eli Lilly. Retail without insurance runs roughly $1,049–$1,135/month. Lilly self-pay vials are cheaper — reported dose-tiered from about $299 at the lowest dose to roughly $449–$599 higher. Brand carries FDA approval and manufacturer quality control.
Compounded
Prepared by state-licensed compounding pharmacies, typically far cheaper — commonly $125–$349/month depending on provider and structure. The trade-off is regulatory: compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or quality. The FDA has issued warning letters to telehealth companies over compounded GLP-1 marketing, and the landscape keeps shifting.
How to weigh it
Price favors compounded; regulatory assurance favors brand. Neither is right for everyone. Decide with a licensed clinician, not on price alone.